Importantly, there arefindings suggesting that pharmacological treatment may modulate inflammatoryactivity, with reductions in IL-6 levels following mood stabilization [68, 69, 70].Collectively, these observations support the idea that BD is characterized bycytokine imbalance, which fluctuates according to clinical state and treatmentstatus, and may contribute to both core mood symptoms and somatic comorbidities. Here, IL6 is linked to Behcet disease.